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ABSTRACT We previously reported a novel phenotype of vancomycin-intermediate
Staphylococcus aureus (VISA), i.e., “slow VISA,” whose colonies appear only after 72 h
of incubation. Slow-VISA strains can be difficult to detect because prolonged incuba-
tion is required and the phenotype is unstable. To develop a method for detection
of slow-VISA isolates, we studied 23 slow-VISA isolates derived from the heteroge-
neous VISA (hVISA) clinical strain Mu3. We identified single nucleotide polymor-
phisms (SNPs) in genes involved in various pathways which have been implicated in
the stringent response, such as purine/pyrimidine synthesis, cell metabolism, and
cell wall peptidoglycan synthesis. We found that mupirocin, which also induces the
stringent response, caused stable expression of vancomycin resistance. On the basis
of these results, we developed a method for detection of slow-VISA strains by
use of 0.032 g/ml mupirocin (Yuki Katayama, 7 March 2017, patent application
PCT/JP2017/008975). Using this method, we detected 53 (15.6%) slow-VISA isolates
among clinical methicillin-resistant S. aureus (MRSA) isolates. In contrast, the VISA
phenotype was detected in fewer than 1% of isolates. Deep-sequencing analysis
showed that slow-VISA clones are present in small numbers among hVISA isolates
and proliferate in the presence of vancomycin. This slow-VISA subpopulation may
account in part for the recurrence and persistence of MRSA infection.
KEYWORDS HA-MRSA, MRSA, hVISA, mupirocin, ppGpp, recurrent infection, slow
VISA, stringent response, tolerance, vancomycin resistance
Two major issues with vancomycin as a treatment for severe methicillin-resistantStaphylococcus aureus (MRSA) infections, including bacteremia, are treatment fail-
ure (1–3) and recurrent infection. The role of bacterial factors in poor outcomes has not
been well defined. To address these issues, we have been focusing on the possible
involvement of a novel phenotype, namely, slow-growing vancomycin-intermediate S.
aureus (“slow VISA”). Slow-VISA strains have the following three major growth proper-
ties: (i) a low growth rate, (ii) resistance to concentrations of vancomycin higher than
those resisted by other extant clinical strains of VISA (MIC  8 g/ml), and (iii) unstable
resistance and colony morphology. rpoB or rpoC mutations can produce the slow-VISA
phenotype (4, 5).
Detection of slow-VISA and heterogeneous VISA (hVISA) strains (6) is problematic.
The vancomycin MICs of hVISA are, by definition, less than 4 g/ml (the susceptibility
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breakpoint for VISA), and thus hVISA is classified as vancomycin-susceptible S. aureus
(VSSA) by MIC testing. Nonetheless, hVISA is distinguishable from VSSA by the presence
of cells resistant to 4 g/ml vancomycin within the cell population, at a frequency of
1  106 or greater. hVISA is thought to be an intermediate step in the development
of resistance from VSSA to VISA. hVISA and slow-VISA cells may also lose their resistance
in the process of repeated isolation and incubation or may not be detected at all under
the standard incubation period of 48 h recommended by the Clinical and Laboratory
Standards Institute (CLSI) guidelines.
In this study, we found numerous mutations in hVISA strain Mu3-derived slow-VISA
strains, in genes involved in various metabolic pathways, including purine/pyrimidine
synthesis and 5P-D-ribosyl-1-pyrophosphate (PRPP) synthesis, as well as in rpoB and
rpoC. These genes are known to be involved in the stringent response, a phenomenon
originally identified in cells subjected to the stress of amino acid starvation, during
which cells undergo massive physiological changes to save energy and conserve
cellular resources (7). Mupirocin also induces the stringent stress response and amino
acid starvation by blocking the charging of isoleucyl-tRNA with isoleucine through
competition with Ile-AMP for isoleucyl-tRNA synthetases. Accumulation of unloaded
isoleucyl-tRNA results in upregulation of the isoleucyl-tRNA synthetase (ileS) gene
(8–10). Mupirocin-mediated amino acid starvation in S. aureus results in downregula-
tion of genes involved in nucleotide biosynthesis, DNA metabolism, energy metabo-
lism, and translation (11). The stringent response is mediated by (p)ppGpp, which
regulates transcription by RNA polymerase (12). The stringent stress response induces
high-level, homogeneous resistance to beta-lactams and depends on the transglyco-
sylase activity of PBP2 (13, 14).
On the basis of these observations, we hypothesized that the mupirocin-induced
stringent stress response could enhance expression of the slow-VISA phenotype. We
developed a method for detecting slow-VISA strains by use of mupirocin and then
investigated the prevalence of slow-VISA strains among clinical isolates by using the
newly developed method.
RESULTS
Mutations present in slow-VISA mutants of Mu3.We identified genetic mutations
other than those in the rpoB and rpoC genes in 23 slow-VISA isolates, derived from the
hVISA strain Mu3 in the presence of 6 g/ml vancomycin for 72 to 144 h (4), and in their
revertants. Mutations were detected in several genes involved in various metabolic
pathways, such as cell envelope synthesis (capP), purine/pyrimidine synthesis (pyrG
[CTP synthase], pykA [pyruvate kinase], and SAHV1000 [GTP pyrophosphokinase]), the
stringent response (PRPP synthesis, prs [ribose-phosphate pyrophosphokinase],
SAHV2320 [ribose 5-phosphate isomerase A], cfxE [ribulose phosphate 3-epimerase],
and SAHV1690 [similar to bifunctional oligoribonuclease] genes), and the Embden-
Meyerhof (EM) pathway (pfk) (see Table S3 in the supplemental material). The pykA and
GTP pyrophosphokinase genes have been associated with the VISA phenotype (5, 15).
We mapped the main genetic mutations identified in the 23 slow-VISA isolates (Fig. 1,
highlighted in red) and their 23 revertants (hVISA) (Fig. 1, highlighted in blue) to the
corresponding metabolic pathways.
The vancomycin MIC was decreased compared to that of the mutant for 21
revertants obtained from the slow-VISA isolates (Table S3). Some mutations in the
large-colony (LC) revertants occurred in the same genes but at different locations
from those in the slow-VISA isolates (rpoB, rpoC, prs, pyrG, and SAHV0253). Mutations
in other genes, for example, the murZ (encoding UDP-N-acetylglucosamine
1-carboxyvinyltransferase, the first enzyme in the biosynthetic pathway for produc-
tion of peptidoglycan monomer units from UDP-GlcNAc), lacR, ccpA (16), SAHV1000,
and rpoC genes, were detected in 10 LC revertants (Fig. 1).
In vivo metabolomics analysis. To determine the effect on metabolomics induced
by mupirocin in the slow-VISA strain Mu3-6R, carrying the RpoB(R512P) mutation, we
performed a comparative analysis of strains expressing three different vancomycin-
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nonsusceptible phenotypes. There were clear phenotypic differences between hVISA
strain Mu3 and slow-VISA strain Mu3-6R, with each expressing different amounts of
products related to the mutations shown in Fig. 1 (Table 1; Table S4). The concentra-
tions of fructose 1,6-P2, fructose 6-P, ribose-5P, ribulose-5P, and PRPP were significantly
decreased in slow-VISA strain Mu3-6R compared to those in hVISA strain Mu3 and VISA
strain Mu3-5-5d in the absence and presence of mupirocin, as expected based on the
mutations shown in Fig. 1.
Nucleotides, especially CTP, UTP, and UDP, used in peptidoglycan synthesis, were
concentrated 4- to 10-fold in slow-VISA strain Mu3-6R compared to those in hVISA
strain Mu3 and VISA strain Mu3-5-5d (Table 1). Low concentrations of GTP were
apparent in slow-VISA strain Mu3-6R and VISA strain Mu3-5-5d in the absence and
presence of mupirocin. However, the decrease in GTP concentration in Mu3-5-5d
carrying TagH(D26E) was not accompanied by induction of (p)ppGpp (undetectable
concentration) (Table 1). Mupirocin induces a decrease in GTP concentration (11, 17)
FIG 1 Proposed model for the mechanism underlying vancomycin resistance in slow-VISA (sVISA) strains. We compared
genotypes between the 23 slow-VISA clinical isolates and 23 revertant hVISA strains shown in Table S3 in the supplemental
material. Mutations in slow-VISA isolates and revertant hVISA strains are highlighted in red and blue, respectively.
TABLE 1 In vivo concentrations of major substances and ppGpp
Strain Phenotype Treatment
Concn (pmol/ml)a
Glucose
Fructose
1,6-P2
Fructose
6-P
Ribose
5-P
Ribulose
5-P PRPP GTP GDP ATP UTP UDP CTP ppGppc
Mu3 hVISA Drug-free 31,657 2,081 44 54 293 1,024 595 229 1,371 441 157 194 ND
Mupirocinb 32,824 560 23 13 328 739 414 154 3,205 1,498 292 1,454 41 6
Mu3-3-5dd VISA Drug-free 36,738 539 25 11 88 615 40 118 315 124 44 159 ND
Mupirocinb 31,140 463 22 10 91 729 44 102 1,004 817 373 309 ND
Mu3-6Re Slow VISA Drug-free 31,384 472 12 13 149 504 245 31 1,415 1,717 498 534 ND
Mupirocinb 30,759 231 11 7 87 283 175 56 2,566 1,364 235 1,362 12 6
aData calculated from two biological replicates. Each value indicates the average. Glucose concentration was used as a control value.
bThe strain was induced with mupirocin (0.032 g/ml) for 30 min. We detected more than 1 nmol/mg of CDW.
cData are means  standard deviations. ND, not detected. ppGpp was measured in triplicate.
dMu3-3-5d showing the VISA phenotype carried the TagH(D26E) mutation.
eMu3-6R showing the slow-VISA phenotype carried the RpoB(R512P) mutation.
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and elicits a response in S. aureus that is linked to the stringent response induced by
(p)ppGpp (8, 18).
Mupirocin-induced stable resistance to and tolerance of vancomycin in slow-
VISA strain Mu3-6R. To evaluate the effect of mupirocin on phenotypic expression of
slow VISA, Mu3-6R was subcultured in an antibiotic-free medium for 2, 5, or 7 days.
When the strain was subcultured for 5 days, more than 90% of the small colonies of
slow-VISA strain Mu3-6R converted to the hVISA phenotype (vancomycin MIC  3
g/ml) (Fig. 2). The expression of the slow-VISA phenotype in Mu3-6R was maintained
by cultivation in brain heart infusion (BHI) broth containing mupirocin at 0.032 or 0.064
g/ml after subculture for 5 days (Fig. 2). The growth curve for Mu3-6R was shifted to
the right (inhibition of growth) at a mupirocin concentration of 0.064 g/ml (Fig. S1),
and therefore a mupirocin concentration of 0.032 g/ml was used for further experi-
ments.
Mupirocin accelerated the growth rate of Mu3-6R in the presence of vanco-
mycin. When slow-VISA strain Mu3-6R was cultured in BHI broth containing 16 g/ml
of vancomycin (1MIC) plus 0.032 g/ml of mupirocin, the growth curve shifted to the
left (i.e., growth was accelerated by 25.5 h) compared to that for growth in BHI broth
without mupirocin (Fig. 3A). The growth curves for strains without the slow-VISA
phenotype were only slightly affected by mupirocin (Fig. 3B to D).
Reduced susceptibility of Mu3-6R to the bactericidal activity of vancomycin is
induced by mupirocin. Time-kill assays were performed to compare the in vitro
activities of vancomycin at 20 g/ml plus mupirocin at 0.032 g/ml against slow-VISA,
VISA, hVISA, and VSSA (MRSA) strains. Mupirocin induced tolerance (i.e., loss of bacte-
ricidal activity) of vancomycin in slow-VISA strains but not in the other strains (Fig. 4).
The same effect on bactericidal activity was observed for vancomycin at 1 or 2 MIC
(data not shown).
Prevalence of clinical slow-VISA isolates among MRSA isolates from blood. We
tested 340 Japanese clinical MRSA isolates (156 blood culture isolates from a single
hospital [Table S1] and 184 randomly selected blood culture isolates collected from 9
hospitals [Table S2]) (19, 20) to determine the prevalence of the slow-VISA phenotype
detected by use of mupirocin induction. Determination of the MIC on BHI agar
containing mupirocin at 0.032 g/ml detected the slow-VISA phenotype after 48 h of
incubation instead of a 72-h or longer incubation in the absence of mupirocin (Table 2
and Fig. 5). In total, we identified 53 (15.6%) slow-VISA isolates (vancomycin MICs of4
mg/liter). Less than 1% of the isolates were VISA strains (Table 2; Tables S1 and S2). The
slow-VISA phenotype showed vancomycin MICs of 4 g/ml after 48 h of incubation,
with increasing resistance to vancomycin after 72 h of incubation. The hVISA strain Mu3
and the VISA strain Mu50 had stable vancomycin MICs of 3 g/ml and 12 g/ml over
FIG 2 Stability of slow-VISA strain Mu3-6R showing high resistance to vancomycin induced by mupirocin. Black and gray
bars indicate slow-VISA and hVISA strains, respectively; n is the number of tested colonies in a population. The y axis shows
the proportion of hVISA cells among slow-VISA cells. The vancomycin MIC (MICVAN) was determined after incubation for
48 h. Mu3-6R was subcultured without or with mupirocin at 0.016, 0.032, or 0.064 g/ml for 2 days (A), 5 days (B), and 7
days (C).
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time, respectively, in the presence and absence of mupirocin (Table 2 and Fig. 5), and
they showed no growth defects.
We confirmed the unstable expression of the slow-VISA phenotype in the absence
of antibiotics. The levels of resistance to vancomycin in six slow-VISA strains (T series
strains in Table 2) were reduced after a 5-day subculture in the absence of antibiotic.
All six revertants (L strains derived from slow-VISA T strains) reverted to the VSSA or
hVISA phenotype.
The zone of inhibition around a 30-g/ml vancomycin disk in the disk diffusion test
was hazy for slow-VISA Mu3-6R on a BHI agar plate (Fig. 5). The 30-g/ml vancomycin
disk diffusion test may be a useful method for detection of slow-VISA strains.
Sequence analysis of emergence of the slow-VISA phenotype from VSSA via
hVISA. We previously reported that a single mutation of RpoB (R512P substitution) is
responsible for nonsusceptibility to vancomycin (4). The Mu3-6R-L1 (hVISA) and Mu3-
6R-L2 (hVISA) revertant mutants showed the large-colony phenotype and were isolated
from slow-VISA strain Mu3-6R after antibiotic-free subculture for 5 days, as described
previously (4). Mu3-6R-L2-6R (slow VISA) was obtained from a pinpoint colony of
Mu3-6R-L2 growing on a BHI agar plate containing vancomycin at 6 g/ml. We
previously reported that when RpoB(R512P) in slow-VISA strain Mu3-6R was changed to
an R512S, R512L, or R512H mutant, it resulted in the hVISA phenotype (4). We used
deep sequencing to study the relationship between phenotype and the proportions of
these various amino acid substitutions in the rpoB gene.
At baseline, Mu3 or Mu3-6R grown in the presence of 6 g/ml of vancomycin carried
99.9% RpoB(R512) or RpoB(R512P), respectively (Fig. 6A). The Mu3-6R-L1 (hVISA)
FIG 3 Increased growth rate of slow-VISA cells under the influence of mupirocin (0.032 g/ml). Cultures were incubated in BHI
broth. Black, drug-free conditions; gray, mupirocin; red, vancomycin at 1 MIC; green, vancomycin at 1 MIC plus mupirocin;
orange, vancomycin at 2 MIC; blue, vancomycin at 2 MIC plus mupirocin. The growth curve was accelerated by 25.5 h
compared to that for growth in BHI containing vancomycin at 16 g/ml (1 MIC) without mupirocin. MICVAN indicates the
vancomycin MIC for the strain.
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revertant mutant cells had 0.20% RpoB(R512P) and 99.8% RpoB(R512S). The Mu3-6R-L2
(hVISA) revertant mutant had 99.9% RpoB(R512S), whereas Mu3-6R-L2-6R, expressing
the slow-VISA phenotype, contained 26.3% RpoB(R512P) and 73.7% RpoB(R512S). Thus,
various RpoB R512 substitution mutants were associated with the slow-VISA Mu3-6R
phenotype (Fig. 6A). The slow-VISA phenotype emerged in the presence of vancomycin,
and the phenotype was lost in the absence of vancomycin, reverting to the hVISA
phenotype (Fig. 6B).
DISCUSSION
We found that several mutations associated with the stringent response are found
in slow-VISA mutant strains. A mupirocin-induced stringent response likely accounts for
detection of the slow-VISA phenotype. The mechanism of resistance to vancomycin of
slow-VISA strains differs from that of VISA strains because mupirocin induces the
phenotype of the former but not the latter, and the associated mutations are different.
For example, slow-VISA strain Mu3-6R has the RpoB(R512P) mutation, whereas VISA
strain Mu3-5-5d has TagH(D26E).
Among the 23 slow-VISA isolates and their revertants, mutations in the rpoB and
rpoC genes occurred more frequently in the slow-VISA strains than in the revertants,
accounting for 32% of the total. Although rpoB is not a regulatory gene, its mutation
drastically changes the transcription profile of the cell—much more than any mutations
in regulators do. An rpoB mutation may act as a regulatory mutation (4, 5, 21, 22).
Besides RpoB mutation, we identified several other mutations in genes involved in
various metabolic pathways, such as purine/pyrimidine synthesis in the pentose phos-
phate pathway. The increase in pools of CTP, UTP, and UMP shown in Table 1 is
associated with the thickness of the cell wall and the VISA phenotype (5, 23–25).
Pyrimidine upregulation has been reported to be normal with respect to the synthesis
of ribosomal components but abnormal in terms of the ppGpp pool (26). Therefore, we
speculate that the vancomycin resistance of slow VISA is due to an increase in pools of
CTP, UTP, and UDP.
FIG 4 Mupirocin induced tolerance of vancomycin only in slow-VISA strain Mu3-6R. A time-kill assay was
performed in BHI broth without a drug (Œ), with vancomycin at 20 g/ml (), and with vancomycin at
20 g/ml plus mupirocin at 0.032 g/ml () against slow-VISA strain Mu3-6R, VISA strain Mu50, hVISA
strain Mu3, and VSSA (MRSA) strain N315ΔIP. Each symbol represents the average CFU (log10)/ml. The
data are means  standard deviations for triplicate wells.
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Mutations of pfk and pykA altered the amounts of the metabolites D-fructose-6P,
D-fructose-1,6P2, and pyruvate in slow-VISA isolates. It is likely that D-fructose-6P pooled
in the slow-VISA strain and contributed to cell wall synthesis.
The capP gene encodes an enzyme that converts UDP-GlcNac to UDP-GlcManNAc
(27). Mutations in this gene may stimulate the pathway of cell wall synthesis at the
expense of purine/pyrimidine synthesis by way of D-fructose-6P. Upregulated glmS
increases production of glucosamine 6-P, which is required for the synthesis of pepti-
doglycan and wall teichoic acids, major components of the S. aureus cell wall (34). These
mutations altering the metabolic pathways of slow VISA may result in activation of cell
wall synthesis, causing thickening of the cell walls and consequent acquisition of
resistance to vancomycin.
We compared the mutations in the 23 revertants (VSSA or hVISA strains) obtained
from slow-VISA cells in the absence of antibiotics. These mutations localized in genes
involved in the stringent response, likely affecting the flow of metabolites in the cell
and promoting cell wall peptidoglycan synthesis by concentrating energy and metab-
olites within that pathway.
Colistin has also been reported to induce vancomycin tolerance that is associated
with quorum sensing. Nevertheless, the mechanisms are different from mupirocin’s
mode of action (28). Further research into the mechanisms by which mupirocin induces
the slow-VISA phenotype is needed.
We identified the following three characteristics of slow-VISA induction by mupiro-
cin: (i) stable resistance to vancomycin, (ii) an accelerated growth rate, and (iii) tolerance
TABLE 2 Detection of slow-VISA cells among clinical MRSA isolates by use of mupirocin
Strain
Phenotypeb Vancomycin MIC (g/ml) by Etest after various periods of incubation
CLSI classification
(48 h)
New
classification
Without antibiotics With mupirocin at 0.032 g/ml
48 h 72 h 96 h 120 h 144 h 48 h 72 h 96 h 120 h 144 h
209P VSSA (MSSA) VSSA (MSSA) 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
N315ΔIP VSSA (MRSA) VSSA (MRSA) 2 2 2 2 2 2 2 2 2 2
Mu3 hVISA hVISA 3 3 3 3 3 3 3 3 3 3
Mu50 VISA VISA 12 12 12 12 12 12 12 12 12 12
MI (HIP5827) VISA VISA 12 12 12 12 12 12 12 12 12 12
Mu3-6R VISA Slow VISA 8 8 12 12 16 16 16 16 16 16
Clinical blood culture isolates
from 9 hospitals
MRSA212 VSSA VSSA 1.5 2 2 2 2 3 3 3 3 3
MRSA84 VSSA hVISA 2 2 3 3 3 3 3 3 3 3
MRSA220 VSSA hVISA 1.5 3 3 3 3 3 3 3 3 3
MRSA192 VSSA hVISA 2 2 2 2 2 2 2 2 2 2
MRSA190 VISA Slow VISA 4 8 8 8 8 12 12 12 12 12
MRSA194 VISA Slow VISA 4 6 8 12 12 8 12 12 12 12
T series clinical blood culture
isolatesa
T12 VISA Slow VISA 4 4 8 8 8 8 8 8 8 8
T15 VISA Slow VISA 4 6 8 8 8 8 8 8 8 8
T61 VISA Slow VISA 4 6 8 8 8 8 8 8 8 8
T89 VISA Slow VISA 4 8 16 16 16 16 16 16 16 16
T122 VISA Slow VISA 4 8 8 8 8 6 6 8 8 8
T123 VISA Slow VISA 4 6 8 8 8 6 8 8 8 8
T12-L hVISA hVISA 3 3 3 3 3 3 3 3 3 3
T15-L hVISA hVISA 3 3 3 3 4 4 4 4 4 4
T61-L hVISA hVISA 3 3 3 3 4 6 6 6 6 6
T89-L hVISA hVISA 3 3 3 3 3 3 3 3 3 3
T122-L VSSA VSSA 2 2 2 2 2 3 3 3 3 3
T123-L VSSA VSSA 2 2 2 2 2 3 3 3 3 3
aT-L strains are revertants obtained from the original clinical strains by subculture for 5 days in the absence of antibiotics.
bSlow-VISA strains showed increasing resistance to vancomycin after 72 h of incubation (vancomycin MICs of 4 g/ml), although they had vancomycin MICs of 4
g/ml after 48 h of incubation. The Mu3 and Mu50 isolates with the hVISA and VISA phenotypes had stable vancomycin MICs of 3 and 12 g/ml, respectively, over
time.
Recurrence and Persistence of Slow-VISA Infection Antimicrobial Agents and Chemotherapy
November 2017 Volume 61 Issue 11 e00452-17 aac.asm.org 7
of bactericidal activity. These were utilized to develop a method for detection of slow
VISA in this study. Using this method, we found that the slow-VISA phenotype was
prevalent in Japanese hospitals, being detected at a frequency of about 15.6% in the
tested MRSA clinical isolates from blood cultures. We also isolated cells with the
FIG 5 (Top) Etest in BHI agar plates containing mupirocin (MUP) at 0.032 g/ml or no drug. After 48 h of
incubation, the slow-VISA strain showed a stable MIC value. (Bottom) Vancomycin (30 g/ml) disk diffusion
test in BHI agar plates. Slow-VISA strains formed a hazy zone around the inhibition zone. The values given
under each panel are the means and standard deviations for the inhibition zone diameter for 3 experiments.
FIG 6 Emergence of the slow-VISA phenotype from VSSA via hVISA or VISA. (A) Proportions of mutations at the 512th residue of the RpoB
gene, which confers high resistance to vancomycin, according to analysis of the rpoB amplicon by deep sequencing of Mu3-6R derivative
clones. (B) The slow-VISA (sVISA) strain converted to VISA and hVISA in the absence of vancomycin.
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slow-VISA phenotype (vancomycin MIC of 16 g/ml) from three VISA strains, namely,
HIP07920 (isolated in 1999, in Rhode Island, from the blood of a patient with bacter-
emia), HIP12864 (isolated in 2003, in Oklahoma, from the blood of a patient with
bacteremia) (29), and P1V44 (isolated in 1999, in Belgium, from sputum of a patient
with cystic fibrosis) (30), in the absence of antibiotics (T. Azechi, unpublished data). Slow
VISA may be prevalent in hospitals worldwide.
We also found that slow VISA emerged in the presence of vancomycin, lost resis-
tance in the absence of vancomycin, and reverted to the hVISA or VSSA phenotype (Fig.
6). Slow-VISA cells were present in small numbers among the hVISA revertants, and
their numbers increased again when they were incubated in the presence of vanco-
mycin. Slow-VISA strains may account in part for recurrent and persistent MRSA
infections (Fig. 6). Rapid detection of slow VISA may be an important tool for predicting
and preventing vancomycin treatment failure.
MATERIALS AND METHODS
Bacterial strains and culture conditions. Bacterial strains used in this study were routinely grown
in BHI medium (Eiken Chemical Co., Ltd., Tochigi, Japan) at 37°C. Two clinical strain collections were
tested for the presence of slow VISA. We selected 156 MRSA blood isolates (described as the T series)
collected from 1987 to 2007, before the use of daptomycin and linezolid in Japan (see Table S1 in the
supplemental material) (20), and we randomly selected 184 MRSA blood isolates from 803 clinical strains
of MRSA collected from January 2008 through May 2011 at nine university hospitals in Japan (Table S2)
(19). The study protocol was approved by the Institutional Review Board.
DNA methods. The standard methods for DNA manipulations were described previously (31).
Genomic DNAs were prepared with a Miniamp kit (Qiagen Inc., Valencia, CA). Routine PCR amplification
was conducted by means of the Expand High-Fidelity system (Roche, Mannheim, Germany).
Antibiotic susceptibility tests. MIC values were determined by Etest (AB Biodisk, Solna, Sweden).
BHI agar was used instead of Mueller-Hinton agar because the former is more supportive of the
expression of the VISA phenotype than are other agar types (32). Plates were then incubated at 37°C and
analyzed after 48 h to 144 h. The Etest to determine the MIC of vancomycin (AB Biodisk, Solna, Sweden),
the 30-g/ml vancomycin agar disk diffusion susceptibility test (Eiken), and population analysis were
carried out on BHI agar following the CLSI guidelines. Mupirocin (Roche) was used for the selection of
slow VISA.
VSSA was defined as S. aureus with a vancomycin MIC of 4 g/ml (CLSI breakpoint) that was
unaffected by prolonged incubation. hVISA was defined as S. aureus with a vancomycin MIC of4 g/ml
(CLSI breakpoint) that was unaffected by prolonged incubation or incubation with mupirocin but had a
subpopulation of cells resistant to 4 g/ml of vancomycin, at a frequency of 1  107 or greater. Slow
VISA was defined as S. aureus with increasing resistance to vancomycin with prolonged incubation of
48 h, to an MIC of 8 g/ml. Other properties of slow VISA are a low growth rate, unstable resistance
and growth phenotypes, tolerance to killing by vancomycin, and a small or pinpoint colony morphology.
VISA was defined as S. aureus with a stable vancomycin MIC of 4 g/ml with prolonged incubation.
Other properties are a stable phenotypic expression, colony morphology, and growth rate.
Emergence of slow-VISA isolates from hVISA strain Mu3. Twenty-three revertants were obtained
from the 23 slow-VISA isolates, derived from Mu3 by selection with 6 g/ml of vancomycin (4), by growth
in the absence of antibiotics after subculture for 5 days. Doubling times and vancomycin MICs were
determined (Table S3).
Genome analysis. We carried out single nucleotide polymorphism (SNP) detection according to a
previously described protocol (4) and by deep sequencing of the amplified rpoB gene according to the
manufacturer’s recommendations (TaKaRa). In brief, 150-bp DNA fragments of the rpoB gene were
amplified by PCR using the primers described previously (4). The amplicon library was constructed by
means of a Nextera XT DNA sample preparation kit, and 150-bp paired-end read sequencing was
performed on a Miseq sequencing platform (Illumina, Inc., San Diego, CA). Reads of 30 Mb were obtained
from each amplicon DNA library. Each read was mapped to the reference rpoB sequence of strain N315.
Metabolome analysis. hVISA strain Mu3, VISA strain Mu3-3-5d (showing a stable vancomycin MIC of
8 g/ml over time), and slow-VISA strain Mu3-6R carrying the RpoB(R512P) mutation each was grown as
described above in defined synthetic medium. VISA strain Mu3-3-5d was isolated from hVISA Mu3 by
selection on vancomycin at 6 g/ml and was found to carry the TagH(D26E) mutation affecting the
teichoic acid export ATP-binding protein (4). The cells were treated with 0.032 g/ml mupirocin, and
samples were harvested immediately after the addition of mupirocin (0 min) and after 30 min. The cells
were washed and quenched, and metabolites were extracted according to the manufacturer’s recom-
mendations (Human Metabolome Technology [HMT], Tokyo, Japan). Briefly, the metabolite extraction
procedure was conducted as follows. Cells were grown in 40 ml of medium in 100-ml Erlenmeyer flasks
with shaking at 180 rpm and 37°C. For each strain, three cultures were incubated in parallel. Cells were
harvested by vacuum filtration through a filter with a 0.45-m pore size. The cells on the filter were
immersed in 2 ml of methanol containing 10 M internal standard solution 1 (HMT). Analytical
biochemistry detection of nucleotides was performed by capillary electrophoresis with mass spectrom-
etry (CE-MS; HMT). Identification and calibration of calibration curves for all the metabolites were carried
out via comparison and measurement of a pure standard compound, (p)ppGpp (Trilink Biotechnology,
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San Diego CA). The results for intracellular metabolites were normalized to the cell dry weight (CDW).
Experiments were performed in duplicate.
Development of a method for detecting slow VISA by use of mupirocin. Measurement of the
appearance rate of hVISA (large-colony [LC] phenotype) from slow VISA (small colonies) and construction
of growth curves were performed as described previously (4). Time-kill analyses were conducted to assess
killing of bacteria (33). In brief, an inoculum of 106 CFU/ml of fresh overnight culture was used.
Four-milliliter aliquots of BHI broth were used for all the time-kill analyses. Bacterial colony counts were
determined in duplicate at baseline and 12, 24, 48, and 72 h after incubation at 37°C. Mupirocin
concentrations ranged from 0.016 to 0.064 g/ml (Fig. S1). The vancomycin MIC was determined by Etest
(AB Biodisk, Solna, Sweden), using BHI agar containing mupirocin at 0.032 g/ml and drug-free BHI agar
(Yuki Katayama, 7 March 2017, patent application PCT/JP2017/008975).
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